From Passion Health Primary Care – Timely, Trustworthy, and Regionally Tailored
Today’s edition highlights key national and local health developments, including FDA drug approvals, emerging COVID trends in Texas, and global disease surveillance—insights that support informed, preventive care in the communities we serve. At Passion Health Primary Care we remain committed to keeping you updated on critical health news and providing the resources you need to stay healthy and informed.
🇺🇸 National Updates
✅ FDA Clears Elevidys for Ambulatory Duchenne Patients Again
The FDA reversed its prior pause and approved resuming Elevidys shipments for ambulatory Duchenne muscular dystrophy patients, ruling that the death in Brazil was unrelated to the therapy. Shipments remain halted for non-ambulatory patients amid ongoing liver safety investigations .
✅ Sarepta Stock Surges as Confidence Returns
Shares jumped over 15% following FDA guidance; analysts remain cautiously optimistic with upgraded ratings, though market sentiment remains fragile .
🏥 Texas Updates
✅ COVID “Nimbus” Variant Drives Summer Surge in Texas
The NB.1.8.1 (Nimbus) variant now dominant in Texas and >25 states, causes extreme sore throat (“razor-blade” throat) and mild symptoms. Vaccines remain protective. Children show higher infection rates but severe illness remains uncommon .
🌍 Global Health Alerts
✅ Mpox Cases Remain at Baseline but Monitored
Global mpox activity has stabilized, though localized clusters persist. Travel-related exposure screening remains recommended in primary care Axios.
💡 Clinical Tips for Providers
• Counsel eligible Duchenne families that ambulatory Elevidys access has resumed—emphasize liver enzyme monitoring and risk mitigation.
• During Nimbus variant surge: test symptomatic patients, especially children; promote vaccination and masking in high-risk environments.
• Include travel history for respiratory illnesses and monitor for mpox travel risk in presentations with rash or fever.
